Clodronic acid in the treatment of postmenopausal osteoporosis

Tanakol R., Yarman S., Bayraktaroglu T., Boztepe H., Alagol F.

CLINICAL DRUG INVESTIGATION, cilt.27, sa.6, ss.419-433, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 6
  • Basım Tarihi: 2007
  • Doi Numarası: 10.2165/00044011-200727060-00005
  • Dergi Adı: CLINICAL DRUG INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.419-433
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Clodronic acid, a first-generation bisphosphonate, has been successfully used in the treatment of high bone turnover states, Paget's disease and osteolytic bone metastases. However, controversies remain over its optimal dosage and method of administration in the treatment of postmenopausal osteoporosis. In this study we aimed to evaluate the effect of clodronic acid treatment for 3 years on bone mineral density (BMD) in women with postmenopausal osteoporosis.